Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

KAERI Technology Enables Grass-Derived Hair Loss Treatment Cosmetics

July 17, 2026 Dr. Michael Lee – Health Editor Health

The Korea Atomic Energy Research Institute (KAERI) has developed a core technology for a hair-loss relief functional cosmetic derived from grass extracts, which reported visible hair regrowth in some users after 35 days of application. This innovation leverages KAERI’s specialized radiation-based biotechnology to enhance the efficacy of natural extracts in treating alopecia and thinning hair.

Key Clinical Takeaways:

  • Mechanism: Uses radiation-induced mutation or processing to optimize the potency of grass-derived extracts.
  • Timeline: User reports indicate observable hair regrowth within a 35-day window.
  • Classification: Developed as a “functional cosmetic,” meaning it focuses on alleviation and prevention rather than a pharmaceutical cure for androgenetic alopecia.

Androgenetic alopecia, the most common form of hair loss, involves a complex pathogenesis where dihydrotestosterone (DHT) shrinks hair follicles, leading to miniaturization and eventual follicle death. While the current standard of care includes FDA-approved treatments like Minoxidil and Finasteride, many patients seek alternatives due to side effects or the need for non-prescription maintenance. The KAERI-led development addresses this clinical gap by utilizing biotechnology to refine natural compounds that can stimulate the scalp’s follicular environment without the systemic risks associated with pharmaceutical hormones.

How Radiation Biotechnology Optimizes Grass Extracts for Hair Growth

The core of this development lies in the foundational technology provided by the Korea Atomic Energy Research Institute. Unlike traditional cosmetics, this product utilizes radiation-based biotechnology to modify the biological activity of plant extracts. By applying specific doses of radiation, researchers can induce mutations or structural changes in the plant’s chemical components, potentially increasing the bioavailability of active compounds that target the dermal papilla—the base of the hair follicle responsible for growth.

This approach focuses on reducing the morbidity of follicle atrophy by improving blood flow and nutrient delivery to the root. According to the PubMed database, the efficacy of plant-derived extracts in treating alopecia often depends on the concentration of polyphenols and flavonoids, which act as antioxidants to protect follicles from oxidative stress. KAERI’s technology ensures these components are optimized for skin penetration.

For patients struggling with scalp inflammation or chronic thinning, the transition from general cosmetics to targeted functional treatments is critical. It is highly recommended to consult with [Board-Certified Dermatologists] to determine if a patient’s hair loss is caused by autoimmune factors, such as alopecia areat, or genetic androgenetic alopecia, as the treatment protocols differ significantly.

Clinical Efficacy and the 35-Day Regrowth Window

The reporting of hair growth after 35 days suggests a rapid acceleration of the anagen (growth) phase of the hair cycle. In a typical hair cycle, the telogen (resting) phase must end before a new hair can emerge. A 35-day window is clinically significant because it aligns with the time required for a follicle to transition from the exogen phase back into active growth.

Metric Standard Cosmetic KAERI-Derived Functional Cosmetic
Active Ingredient General botanical oils Radiation-optimized grass extracts
Primary Goal Surface hydration/aesthetic Follicle stimulation/alleviation
Reported Response Variable/Long-term Visible regrowth in ~35 days

While the results are promising, these products are categorized as functional cosmetics rather than drugs. This means they are designed to support the scalp environment and alleviate symptoms rather than reverse permanent follicle scarring. This distinction is vital for patient expectations. Those experiencing sudden, patchy hair loss should avoid self-treating and instead seek a diagnostic workup at [Specialized Trichology Centers] to rule out underlying systemic health issues.

Funding, Transparency, and the B2B Tech Transfer

The development was a collaborative effort where the Korea Atomic Energy Research Institute provided the original source technology, which was then transferred to a private manufacturing firm for commercialization. This model of public-to-private tech transfer is common in South Korean biotechnology to accelerate the delivery of government-funded research to the consumer market.

The use of radiation in this context is not for the final product’s radioactivity, but as a tool for bio-modification during the extraction process. This is a recognized scientific method used in agriculture and medicine to create more potent strains of plants or more stable pharmaceutical compounds. For companies looking to integrate such high-tech biological extracts into their own lines, navigating the regulatory landscape of the Ministry of Food and Drug Safety (MFDS) is essential. Pharmaceutical distributors and cosmetic manufacturers are increasingly employing [Healthcare Compliance Attorneys] to ensure that “functional” claims meet strict regulatory evidentiary standards to avoid litigation.

Future Trajectory of Radiation-Enhanced Therapeutics

The success of the grass-extract project suggests a broader potential for radiation biotechnology in dermatology. By manipulating the molecular structure of botanical compounds, researchers may be able to create more effective treatments for other skin conditions, including psoriasis and severe dermatitis, without relying on synthetic steroids. The ability to pinpoint specific mutations that trigger growth factors could lead to a new class of non-invasive, non-hormonal hair restoration tools.

As these technologies move from the lab to the pharmacy shelf, the focus will shift toward double-blind, placebo-controlled trials to establish a precise statistical probability of success across different age groups and ethnicities. Until such large-scale clinical data is available, these products should be viewed as complementary therapies. Patients are encouraged to integrate these innovations into a broader healthcare plan managed by vetted medical professionals found through our directory of specialized clinics.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Worth a look

  • Common Cold Vaccine Candidate Shows Promise in Phase 1 Trials
  • HPV Vaccination: Pharmacists Should Prepare Now

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service